IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v12y2011i6p553-562.html
   My bibliography  Save this article

How removing prescription drugs from reimbursement lists increases the pharmaceutical expenditures for alternatives

Author

Listed:
  • Özden Gür Ali
  • Başak Topaler

Abstract

No abstract is available for this item.

Suggested Citation

  • Özden Gür Ali & Başak Topaler, 2011. "How removing prescription drugs from reimbursement lists increases the pharmaceutical expenditures for alternatives," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 12(6), pages 553-562, December.
    • Handle: RePEc:spr:eujhec:v:12:y:2011:i:6:p:553-562
    DOI: 10.1007/s10198-010-0270-2
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1007/s10198-010-0270-2
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.1007/s10198-010-0270-2?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Ryan, Mandy & Yule, Brian, 1990. "Switching drugs from prescription-only to over-the-counter availability: economic benefits in the United Kingdom," Health Policy, Elsevier, vol. 16(3), pages 233-239, December.
    2. Huttin, C. & Andral, J., 2000. "How the reimbursement system may influence physicians' decisions results from focus groups interviews in France," Health Policy, Elsevier, vol. 54(2), pages 67-86, November.
    3. Özden Gür Ali & Murali Mantrala, 2010. "Pharma rebates, pharmacy benefit managers and employer outcomes," Health Care Management Science, Springer, vol. 13(4), pages 281-293, December.
    4. Andersson, Karolina & Petzold, Max Gustav & Sonesson, Christian & Lonnroth, Knut & Carlsten, Anders, 2006. "Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures?: Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002," Health Policy, Elsevier, vol. 79(2-3), pages 231-243, December.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Katherine Baicker & Theodore Svoronos, 2019. "Testing the Validity of the Single Interrupted Time Series Design," NBER Working Papers 26080, National Bureau of Economic Research, Inc.
    2. Han, Euna & Chae, Su-Mi & Kim, Nam-Soon & Park, Sylvia, 2015. "Effects of pharmaceutical cost containment policies on doctors’ prescribing behavior: Focus on antibiotics," Health Policy, Elsevier, vol. 119(9), pages 1245-1254.
    3. Paraponaris, A. & Verger, P. & Desquins, B. & Villani, P. & Bouvenot, G. & Rochaix, L. & Gourheux, J. C. & Moatti, J. P. AU -, 2004. "Delivering generics without regulatory incentives?: Empirical evidence from French general practitioners about willingness to prescribe international non-proprietary names," Health Policy, Elsevier, vol. 70(1), pages 23-32, October.
    4. Barros, Pedro Pita & Nunes, Luis C., 2010. "The impact of pharmaceutical policy measures: An endogenous structural-break approach," Social Science & Medicine, Elsevier, vol. 71(3), pages 440-450, August.
    5. Dong Woo Ko & Young Han Bae & Jayoung Han, 2018. "Social Exclusion and Switching Barriers in Medicare Part D Choices," Sustainability, MDPI, vol. 10(7), pages 1-10, July.
    6. Kwon, Hye-Young & Hong, Ji-Min & Godman, Brian & Yang, Bong-Min, 2013. "Price cuts and drug spending in South Korea: The case of antihyperlipidemic agents," Health Policy, Elsevier, vol. 112(3), pages 217-226.
    7. Han, Euna & Park, Sun-Young & Lee, Eui-Kyung, 2016. "Assessment of the Price–Volume Agreement Program in South Korea," Health Policy, Elsevier, vol. 120(10), pages 1209-1215.
    8. Fiorentini, Gianluca & Bruni, Matteo Lippi & Mammi, Irene, 2022. "The same old medicine but cheaper: The impact of patent expiry on physicians’ prescribing behaviour," Journal of Economic Behavior & Organization, Elsevier, vol. 204(C), pages 37-68.
    9. Sabine Vogler & Guillaume Dedet & Hanne Bak Pedersen, 2019. "Financial Burden of Prescribed Medicines Included in Outpatient Benefits Package Schemes: Comparative Analysis of Co-Payments for Reimbursable Medicines in European Countries," Applied Health Economics and Health Policy, Springer, vol. 17(6), pages 803-816, December.
    10. Chris Bojke & Hugh Gravelle & Karen Hassell & Zoe Whittington, 2004. "Increasing patient choice in primary care: the management of minor ailments," Health Economics, John Wiley & Sons, Ltd., vol. 13(1), pages 73-86, January.
    11. Burapadaja, Siriporn & Kawasaki, Naohito & Charumanee, Suporn & Ogata, Fumihiko, 2007. "Effects of essential medicines on cardiovascular products available for the market in Thailand," Health Policy, Elsevier, vol. 84(1), pages 67-74, November.
    12. Panos Kouvelis & Yixuan Xiao & Nan Yang, 2015. "PBM Competition in Pharmaceutical Supply Chain: Formulary Design and Drug Pricing," Manufacturing & Service Operations Management, INFORMS, vol. 17(4), pages 511-526, October.
    13. Vincenzo Atella & Peter R. Noyce & Ellen Schafheutle & Karen Hassell, 2005. "Affordability of Medicines and Patients' Cost Reduction Behaviors: Empirical Evidence Based on SUR Estimates from Italy and the United Kingdom," CEIS Research Paper 71, Tor Vergata University, CEIS.
    14. Skipper, Niels, 2012. "On reimbursement reforms and stockpiling of prescription drugs: The case of insulin," Health Policy, Elsevier, vol. 106(3), pages 233-240.
    15. Yuqing Tang & Chaojie Liu & Junjie Liu & Xinping Zhang & Keyuan Zuo, 2018. "Effects of County Public Hospital Reform on Procurement Costs and Volume of Antibiotics: A Quasi-Natural Experiment in Hubei Province, China," PharmacoEconomics, Springer, vol. 36(8), pages 995-1004, August.
    16. Katherine Baicker & Theodore Svoronos, 2019. "Testing the Validity of the Single Interrupted Time Series Design," CID Working Papers 364, Center for International Development at Harvard University.
    17. Carl Rudolf Blankart & Tom Stargardt, 2017. "Preferred supplier contracts in post-patent prescription drug markets," Health Care Management Science, Springer, vol. 20(3), pages 419-432, September.
    18. Mats A. Bergman & David Granlund & Niklas Rudholm, 2016. "Reforming the Swedish pharmaceuticals market: consequences for costs per defined daily dose," International Journal of Health Economics and Management, Springer, vol. 16(3), pages 201-214, September.
    19. Keith Finlay & Charles Stoecker & Scott Cunningham, 2015. "Willingness-To-Accept Pharmaceutical Retail Inconvenience: Evidence from a Contingent Choice Experiment," PLOS ONE, Public Library of Science, vol. 10(5), pages 1-10, May.
    20. Andersson, Karolina & Bergstrom, Gina & Petzold, Max G. & Carlsten, Anders, 2007. "Impact of a generic substitution reform on patients' and society's expenditure for pharmaceuticals," Health Policy, Elsevier, vol. 81(2-3), pages 376-384, May.

    More about this item

    Keywords

    Pharmaceutical expenditures; Reimbursement; Health policy; Cost-effectiveness; Substitution with alternatives; I18 - Government Policy; Regulation; Public Health; N34 - Europe: 1913-; C22 - Time-Series Models;
    All these keywords.

    JEL classification:

    • I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health
    • N34 - Economic History - - Labor and Consumers, Demography, Education, Health, Welfare, Income, Wealth, Religion, and Philanthropy - - - Europe: 1913-
    • C22 - Mathematical and Quantitative Methods - - Single Equation Models; Single Variables - - - Time-Series Models; Dynamic Quantile Regressions; Dynamic Treatment Effect Models; Diffusion Processes

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:12:y:2011:i:6:p:553-562. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.